aid: bambusa-therapeutics
name: Bambusa Therapeutics
description: 'Bambusa Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in the
  Boston Seaport, founded in 2024 by Shanshan Xu and Helmut Jeggle to develop next-generation bispecific
  antibodies for immunological and inflammatory (I&I) diseases. Its antibody-engineering platform combines
  half-life extension with high-concentration subcutaneous delivery, and its pipeline spans dermatology,
  respiratory, gastroenterology and rheumatology — led by BBT-001 (IL-31 x IL-4Ralpha, in a Phase 1b/2a
  atopic dermatitis trial) and BBT-002 for COPD. The company raised a Series Seed in 2024, an approximately
  $90M Series A led by RA Capital Management in February 2025, and an oversubscribed Series A-2 in November
  2025. It is a therapeutics developer, not a software vendor, and publishes no public API, SDK or developer
  program.'
url: https://raw.githubusercontent.com/api-evangelist/bambusa-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Clinical Trials
- Drug Development
- Antibodies
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/bambusa-therapeutics-domain-security.yml
- type: Website
  url: https://bambusatx.com/
- type: About
  url: https://bambusatx.com/about/
- type: SecondaryMarket
  url: https://forgeglobal.com/bambusa-therapeutics_stock/
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Bambusa is a 2024-founded clinical-stage antibody developer whose only web property,
    bambusatx.com, is a marketing site sitting entirely behind a SiteGround captcha (every
    path, including /, answers 202 with an sgcaptcha redirect), while DNS resolves no
    api./docs./developers./portal. host and no company GitHub organization exists — the
    product is a bispecific-antibody pipeline, not software, so there is no API to publish.
  evidence:
  - url: https://bambusatx.com/openapi.json
    status: 202
  - url: https://bambusatx.com/.well-known/agent-card.json
    status: 202
  - url: https://bambusatx.com/.well-known/security.txt
    status: 202
  - url: https://bambusatx.com/
    status: 202
  checked: '2026-08-06'